PLC Systems’ RenalGuard® to be Featured in Contrast-Induced Kidney Injury Session at TCT 2012
MILFORD, Mass.--(BUSINESS WIRE)--Oct 18, 2012--PLC Systems Inc. (OTCBB: PLCSF), a medical device company focused on innovative technologies for the cardiac and vascular markets, today announced that its lead product, RenalGuard ®, will be featured during , a 90-minute discussion session at Transcatheter Cardiovascular Therapeutics (TCT) 2012, being held October 22-26, 2012 at the Miami Beach Convention Center.
As part of its participation in this important conference, PLC will demonstrate RenalGuard in its booth (#805) and RenalGuard will also be displayed in the ACIST Medical Systems booth (#673) and in the Twins and Martin Equipment booth (#692) through Girlow USA. ACIST is PLC’s distributor in France and Germany, and Girlow is PLC's distributor in Latin and South America excluding Brazil.
Mark R. Tauscher, president and chief executive officer of PLC Systems, said, “We continue to see an increased focus worldwide on the issue of acute kidney injury caused by the use of contrast during imaging procedures, otherwise known as contrast-induced nephropathy (CIN). The development of CIN results in a range of serious and potentially deadly outcomes in patients who already have compromised kidney function, and clinical data continue to show that the use of RenalGuard and its associated therapy can reduce the incidence of this condition in at-risk patients.” Mr. Tauscher continued, “This year’s TCT expects to attract a large international audience, which will provide us with increased exposure in countries where we are currently selling RenalGuard, including Latin America, South America and Europe. Current projections indicate that more than 60% of this year’s attendees will come from countries where RenalGuard is currently available through our network of distributors.” is a 90-minute discussion of prevention techniques and therapies including RenalGuard and its associated matched fluid replacement therapy, and will include the principal investigators of the MYTHOS trial, Dr. Antonio Bartorelli, and the principal investigator of the REMEDIAL II trial, Dr. Carlo Briguori. Both trials demonstrated that patients treated with RenalGuard had a lower incidence rate of CIN compared with those treated with the current standard of care. It is one of a number of sessions related to CIN at this year’s conference, and takes place Friday, October 26, from 12:15 p.m. to 1:45 p.m. local time.
TCT is sponsored by the Cardiovascular Research Foundation, and more than 12,000 clinicians and professionals from around the world are expected to attend this year’s event.
PLC management will be available to meet with members of the investment community during the conference. Investors may visit PLC’s booth, or call Kim Sutton Golodetz of LHA at 212-838-3777 to schedule a one-on-one meeting.
About PLC Systems Inc. PLC Medical Systems, Inc., the operating subsidiary of PLC Systems Inc., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's lead product, RenalGuard®, significantly reduces the onset of CIN in at-risk patients undergoing certain cardiac and vascular imaging procedures. CIN is a form of acute kidney injury resulting from toxic contrast agents that occurs in 10% to 20% of at-risk patients. RenalGuard is CE-marked and is being sold in Europe and certain countries around the world via a network of distributors. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing CIN. The CIN-RG RenalGuard pivotal study is underway in the U.S. to support a planned Premarket Approval filing with the U.S. Food and Drug Administration.
Additional company information can be found at www.plcmed.com.
This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2011, a copy of which is on file with the SEC. PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc.CONTACT: LHA Kim Sutton Golodetz, 212-838-3777 Kgolodetz@lhai.com or Bruce Voss, 310-691-7100 Bvoss@lhai.com @LHA_IR_PR or PLC Systems Inc.
Gregory Mann, Chief Financial Officer, 508-541-8800 firstname.lastname@example.org KEYWORD: UNITED STATES NORTH AMERICA FLORIDA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH CARDIOLOGY CLINICAL TRIALS MEDICAL DEVICES SOURCE: PLC Systems Inc. Copyright Business Wire 2012 PUB: 10/18/2012 08:00 AM/DISC: 10/18/2012 08:00 AM http://www.businesswire.com/news/home/20121018005027/